| Literature DB >> 27697982 |
Jaffer A Ajani, Thomas A D'Amico, Khaldoun Almhanna, David J Bentrem, Joseph Chao, Prajnan Das, Crystal S Denlinger, Paul Fanta, Farhood Farjah, Charles S Fuchs, Hans Gerdes, Michael Gibson, Robert E Glasgow, James A Hayman, Steven Hochwald, Wayne L Hofstetter, David H Ilson, Dawn Jaroszewski, Kimberly L Johung, Rajesh N Keswani, Lawrence R Kleinberg, W Michael Korn, Stephen Leong, Catherine Linn, A Craig Lockhart, Quan P Ly, Mary F Mulcahy, Mark B Orringer, Kyle A Perry, George A Poultsides, Walter J Scott, Vivian E Strong, Mary Kay Washington, Benny Weksler, Christopher G Willett, Cameron D Wright, Debra Zelman, Nicole McMillian, Hema Sundar.
Abstract
Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of death from cancer in the world. Several advances have been made in the staging procedures, imaging techniques, and treatment approaches. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Gastric Cancer provide an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. This manuscript discusses the recommendations outlined in the NCCN Guidelines for staging, assessment of HER2 overexpression, systemic therapy for locally advanced or metastatic disease, and best supportive care for the prevention and management of symptoms due to advanced disease.Entities:
Mesh：
Year: 2016 PMID： 27697982 DOI： 10.6004/jnccn.2016.0137
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908